Shijia Ge

693 total citations · 1 hit paper
11 papers, 251 citations indexed

About

Shijia Ge is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Shijia Ge has authored 11 papers receiving a total of 251 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Infectious Diseases, 3 papers in Epidemiology and 2 papers in Surgery. Recurrent topics in Shijia Ge's work include Tuberculosis Research and Epidemiology (6 papers), SARS-CoV-2 and COVID-19 Research (4 papers) and Diagnosis and treatment of tuberculosis (2 papers). Shijia Ge is often cited by papers focused on Tuberculosis Research and Epidemiology (6 papers), SARS-CoV-2 and COVID-19 Research (4 papers) and Diagnosis and treatment of tuberculosis (2 papers). Shijia Ge collaborates with scholars based in China, United States and Switzerland. Shijia Ge's co-authors include Xinhua Chen, Juan Yang, Ruijia Sun, Hongjie Yu, Wanying Lu, Daniel T. Leung, Zeyao Zhao, Andrew S. Azman, Xiangyanyu Xu and Yuyang Tian and has published in prestigious journals such as Nature Genetics, Clinical Infectious Diseases and Journal of Clinical Microbiology.

In The Last Decade

Shijia Ge

8 papers receiving 243 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Global landscape of SARS-CoV-2 genomic surveillance and data sharing

2022 137 citations Andrew S. Azman, Xinhua Chen et al. Nature Genetics profile →

Peers

Countries citing papers authored by Shijia Ge

Since Specialization

Citations

This map shows the geographic impact of Shijia Ge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shijia Ge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shijia Ge more than expected).

Fields of papers citing papers by Shijia Ge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shijia Ge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shijia Ge. The network helps show where Shijia Ge may publish in the future.

Co-authorship network of co-authors of Shijia Ge

This figure shows the co-authorship network connecting the top 25 collaborators of Shijia Ge. A scholar is included among the top collaborators of Shijia Ge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shijia Ge. Shijia Ge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Prevalence, Progression, and Treatment of Asymptomatic Tuberculosis: A Prospective Cohort Study in Lanxi County, Zhejiang Province, China 2025 ·Open Forum Infectious Diseases ·Shijia Ge, Kui Liu, (unknown), Zhen Feng, Songhua Chen, Yaling Feng, Guoyong Jiang, Zhicheng Yu, Lingyun Song, Lingyun Shao, Yilin Zhang, Feng Sun, Tao Li, Bin Chen, (unknown), Wenhong Zhang	0
2	Enhancing Implicit Neural Representations via Symmetric Power Transformation 2025 ·Proceedings of the AAAI Conference on Artificial Intelligence ·Weixiang Zhang, (unknown), Chengwei Ren, Shijia Ge, Mingzi Wang, Zhi Wang	0
3	Assessing hepatotoxicity in novel and standard short regimens for rifampicin-resistant tuberculosis: Insights from the TB-TRUST and TB-TRUST-plus trials 2024 ·International Journal of Infectious Diseases ·Lingyun Song, Yilin Zhang, Feng Sun, (unknown), (unknown), Shijia Ge, Zhen Feng, Rong Li, Hongying Yu, (unknown), Wenhong Zhang	2
4	Ability of the MeltPro MTB/PZA Assay to Detect Susceptibility to Pyrazinamide in Rifampin-Resistant Tuberculosis Patients 2023 ·Microbiology Spectrum ·Rong Li, Yang Li, Xinchang Chen, (unknown), Hongying Yu, (unknown), Qianhong Wu, Mingying Xiao, Shijia Ge, Yilin Zhang, Zhen Feng, Qingge Li, Ye Xu, (unknown), Feng Sun, Wenhong Zhang	0
5	Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial 2023 ·BMC Infectious Diseases ·Zhen Feng, Miao Yan, Ying Peng, Feng Sun, Yilin Zhang, Rong Li, Shijia Ge, Xinchang Chen, Lingyun Song, Yang Li, Xiaomeng Wang, Wenhong Zhang	3
6	Rapid Detection of Extensive Drug Resistance by Xpert MTB/XDR Optimizes Therapeutic Decision-Making in Rifampin-Resistant Tuberculosis Patients 2023 ·Journal of Clinical Microbiology ·Xinchang Chen, Rong Li, Shijia Ge, Yang Li, (unknown), (unknown), Yilin Zhang, Jingwen Jiang, Zhen Feng, (unknown), (unknown), (unknown), David H. Persing, Jiazhen Chen, Yi‐Wei Tang, Feng Sun, Wenhong Zhang	7
7	Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint 2022 ·BMC Medicine ·Xinhua Chen, Wei Wang, Xinghui Chen, Qianhui Wu, Ruijia Sun, Shijia Ge, Nan Zheng, Wanying Lu, Juan Yang, Lance E. Rodewald, Hongjie Yu	14
8	Global landscape of SARS-CoV-2 genomic surveillance and data sharing breakdown → 2022 ·Nature Genetics ·(unknown), Andrew S. Azman, Xinhua Chen, Junyi Zou, Yuyang Tian, Ruijia Sun, Xiangyanyu Xu, Yani Wu, Wanying Lu, Shijia Ge, Zeyao Zhao, Juan Yang, Daniel T. Leung, Daryl Domman, Hongjie Yu	137
9	Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis 2021 ·Clinical Infectious Diseases ·Xinhua Chen, Zhiyuan Chen, Andrew S. Azman, Ruijia Sun, Wanying Lu, Nan Zheng, Jiaxin Zhou, Qianhui Wu, Xiaowei Deng, Zeyao Zhao, Xinghui Chen, Shijia Ge, Juan Yang, Daniel T. Leung, Hongjie Yu	67
10	Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial 2021 ·BMC Infectious Diseases ·(unknown), Feng Sun, Yang Li, Jiazhen Chen, Xinchang Chen, Rong Li, Shijia Ge, Yanlin Zhao, Wenhong Zhang	11
11	Neutralizing Antibodies Against SARS-CoV-2 Variants Induced by Natural Infection or Vaccination: A Systematic Review and Individual Data Meta-Analysis 2021 ·SSRN Electronic Journal ·Xinhua Chen, Zhiyuan Chen, Andrew S. Azman, Ruijia Sun, Wanying Lu, Nan Zheng, Jiaxin Zhou, Qianhui Wu, Xiaowei Deng, Zeyao Zhao, Xinghui Chen, Shijia Ge, Juan Yang, Daniel T. Leung, Hongjie Yu	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact